Vertex Pharmaceuticals (BSP:VRTX34) SpecialCharges


BSP:VRTX34 Vertex Pharmaceuticals Inc BSP:VRTX34
86 GF Score
Price R$621.43
GF Value R$641.62
Valuation Fairly Valued
! 5 Warning Signs
View Full Analysis

What is Vertex Pharmaceuticals SpecialCharges?

Special Charges only applies to banks.

BSP:VRTX34
86GF Score
Vertex Pharmaceuticals Inc BSP:VRTX34
SpecialCharges is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Vertex Pharmaceuticals (BSP:VRTX34) Overvalued in 2026?

Based on GuruFocus' analysis, Vertex Pharmaceuticals stock appears to be undervalued. The current stock price of R$621.43 is trading 3.1% below its estimated GF Value™ of R$641.62. GuruFocus considers Vertex Pharmaceuticals to be Fairly Valued.

Key valuation signals for BSP:VRTX34:

  • SpecialCharges:
  • GF Value™: R$641.62 vs. price of R$621.43 (3.1% below fair value)
  • GF Score™: 86/100 with 5 warning signs

No single metric tells the full story. See the BSP:VRTX34 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Vertex Pharmaceuticals Business Description

Address 50 Northern Avenue, Boston, MA, USA, 02210
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio, and Alyftrek for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease, and Journavx, a non-opioid pain medication approved for the treatment of moderate-to-severe acute pain in adults. Additionally, Vertex is evaluating small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
86GF Score

Get the complete analysis for BSP:VRTX34

SpecialCharges is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

R$621.43
Price
R$641.62
GF Value